Unichem Laboratories · NSE: UNICHEMLAB · BSE: 506690

Q4 FY21 results · Jan–Mar 2021

Unichem Laboratories reported revenue from operations of ₹274.12 crore (down 14.4% from Q4 FY20) and net loss of ₹0.41 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.

Consolidated · ₹ crore
ItemQ4 FY21Q4 FY20YoYQ3 FY21QoQ
Revenue from operations274.12320.23−14.4%326.28−16.0%
Other income7.8311.82−33.8%15.61−49.8%
Total income281.95332.05−15.1%341.89−17.5%
Profit before share of associates & JVs and tax3.20(0.17)Turned profit23.64−86.5%
Share of profit/(loss) of associates & JVs(0.24)0.61(0.15)
Net profit for the period(0.41)(17.19)Loss narrowed23.56Turned loss
EPS, basic (₹)(0.06)(2.44)Loss narrowed3.35Turned loss
Net margin (%)-0.1-5.47.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ4 FY21Q4 FY20YoYQ3 FY21QoQ
Revenue from operations261.09216.07+20.8%311.18−16.1%
Other income4.9119.13−74.4%13.32−63.2%
Total income265.99235.20+13.1%324.51−18.0%
Profit before tax12.43(11.54)Turned profit25.61−51.5%
Net profit for the period0.86(11.55)Turned profit30.43−97.2%
EPS, basic (₹)0.12(1.65)Turned profit4.32−97.2%
Net margin (%)0.3-5.39.8
Consolidated
Filed with BSE
31 May 2021, 08:54 IST
Board meeting
29 May 2021
Period
01 Jan 2021 to 31 Mar 2021
Review status
Audited
Source
XBRL filing on BSE
Standalone
Filed with BSE
31 May 2021, 08:54 IST
Board meeting
29 May 2021
Period
01 Jan 2021 to 31 Mar 2021
Review status
Audited
Source
XBRL filing on BSE